Given that several RNAi drugs are either approved by the US Food and Drug Administration (FDA) or in clinical trials (Zhang et al., 2021), and we have recently achieved successful delivery of nucleic acids into prostate cancer cells using mesoporous silica nanoparticles (Maestas-Olguin et al., 2023), strategies for delivering STEAP4 siRNA or antisense oligonucleotides to CRC cells should also be considered. This evidence concerns the gene STEAP4 and prostate carcinoma.